Key Metrics of Regeneron Pharmaceuticals
Revenue$13.1B▲ 7.8% YoYFY 2023
Operating income$4.0B▼ 14.6% YoY
Net profit$4.0B▼ 8.9% YoY
Shareholders' equity$26.0B
Market cap$84.3BREGN · $818.77
Competitors10identified
About Regeneron Pharmaceuticals
Sectors
Company details
- Website
- regeneron.com
- Founded
- 1991
- Listed
- Nasdaq: REGN (since 1991)
Operational Areas of Regeneron Pharmaceuticals
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameRegeneron Pharmaceuticals Inc.
TickerREGN
ExchangeNasdaq
CountryUnited States
SEC CIK0000872589
Listed since1991
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Websitehttps://www.regeneron.com
US market & SEC filings
REGN · Nasdaq · SEC CIK 0000872589
Last price · 30 Oct 2026
$818.77
+0.68%
Market cap$84.3B
P/E23.5On FY 2023 diluted EPS
Volume789,306
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 1991
REGN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeEastview
GSTIN—
Email—
Websitehttps://www.regeneron.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Regeneron Pharmaceuticals
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Similar companies
K
Koninklijke Philips N.V. NY Registry SharesPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
L
Labcorp Holdings Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
W
West Pharmaceutical Services Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Silicon LaboratoriesPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
A
Arrowhead PharmaceuticalsPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
A
Amneal Pharmaceuticals, Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
A
Alnylam PharmaceuticalsPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
I
IncytePharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.